These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 16952014)
1. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014 [TBL] [Abstract][Full Text] [Related]
2. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Anderson MJ; Shelton GD; Cavenee WK; Arden KC Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1589-94. PubMed ID: 11171995 [TBL] [Abstract][Full Text] [Related]
3. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Ren YX; Finckenstein FG; Abdueva DA; Shahbazian V; Chung B; Weinberg KI; Triche TJ; Shimada H; Anderson MJ Cancer Res; 2008 Aug; 68(16):6587-97. PubMed ID: 18701482 [TBL] [Abstract][Full Text] [Related]
4. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR Genes Dev; 2004 Nov; 18(21):2614-26. PubMed ID: 15489287 [TBL] [Abstract][Full Text] [Related]
5. Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. Lagha M; Sato T; Regnault B; Cumano A; Zuniga A; Licht J; Relaix F; Buckingham M BMC Genomics; 2010 Dec; 11():696. PubMed ID: 21143873 [TBL] [Abstract][Full Text] [Related]
6. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Sublett JE; Jeon IS; Shapiro DN Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639 [TBL] [Abstract][Full Text] [Related]
7. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879 [TBL] [Abstract][Full Text] [Related]
8. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Frascella E; Toffolatti L; Rosolen A Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061 [TBL] [Abstract][Full Text] [Related]
9. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma. Hu Q; Yuan Y; Wang C PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156 [TBL] [Abstract][Full Text] [Related]
10. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Lagutina I; Conway SJ; Sublett J; Grosveld GC Mol Cell Biol; 2002 Oct; 22(20):7204-16. PubMed ID: 12242297 [TBL] [Abstract][Full Text] [Related]
11. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119 [TBL] [Abstract][Full Text] [Related]
12. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Bennicelli JL; Edwards RH; Barr FG Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596 [TBL] [Abstract][Full Text] [Related]
13. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
14. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145 [TBL] [Abstract][Full Text] [Related]
15. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Barr FG Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823 [TBL] [Abstract][Full Text] [Related]
16. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Wang W; Slevin M; Kumar S; Kumar P Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327 [TBL] [Abstract][Full Text] [Related]
17. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Keller C; Hansen MS; Coffin CM; Capecchi MR Genes Dev; 2004 Nov; 18(21):2608-13. PubMed ID: 15520281 [TBL] [Abstract][Full Text] [Related]
18. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Xia SJ; Rajput P; Strzelecki DM; Barr FG Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479 [TBL] [Abstract][Full Text] [Related]
19. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659 [TBL] [Abstract][Full Text] [Related]
20. Transgenic rescue of congenital heart disease and spina bifida in Splotch mice. Li J; Liu KC; Jin F; Lu MM; Epstein JA Development; 1999 Jun; 126(11):2495-503. PubMed ID: 10226008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]